Aravive Appoints Michael W. Rogers to Board of Directors
HOUSTON, Sept. 17, 2020 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing transformative therapeutics, today announced that [...]
NuCana Announces Pricing of a Public Offering of American Depositary Shares
EDINBURGH, United Kingdom, Sept. 17, 2020 (GLOBE NEWSWIRE) — NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment […]
LGI Homes Opens New Section at a Popular Community in the Houston Market
COVE, Texas, Sept. 17, 2020 (GLOBE NEWSWIRE) — LGI Homes, Inc. (Nasdaq:LGIH) announced it is now selling a new section […]
Passage Bio Announces Publication of Preclinical Gene Therapy Study Data from Frontotemporal Dementia Program
Data Show Single Injection of AAV-Granulin Gene Therapy into Central Nervous System Reverses Frontotemporal Dementia Pathology Caused by Granulin Mutations and […]
Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid Tumors
DURHAM, N.C. and PARIS, Sept. 17, 2020 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology developing […]
ALX Oncology Added to Russell 2000® and 3000® Indexes
BURLINGAME, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company […]
Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 17, 2020 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: […]
Hygo Energy Transition Ltd. Launches Initial Public Offering
Golar LNG Limited (“Golar”) announces today that Hygo Energy Transition Ltd. (NASDAQ: HYGO) (“Hygo”), a joint venture with Stonepeak Infrastructure […]
Puyi Inc. to Announce Audited Financial Results For Fiscal Year 2020 and Host Conference Call on September 28, 2020
GUANGZHOU, China, Sept. 17, 2020 (GLOBE NEWSWIRE) — Puyi Inc. (“Puyi” or the “Company”) (NASDAQ: PUYI), a leading third-party wealth […]
Mersana Therapeutics Reports Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study
– Maintained 34% objective response rate and 79% disease control rate, including two complete responses – XMT-1536 continues to be generally […]
